Clicinal analysis of Cetuximab in the treatment of elderly k-RAS wild-type metastatic colorectal cancer
TAN Qin1 REN Shun’an2 ZHOU Rengui1▲
1.Department of Hematology and Oncology, No. 904 Hospital of the Joint Logistics Support Force of the Liberation Army, Jiangsu Province, Wuxi 214000, China;
2.Department of Respiratory Medicine, No. 904 Hospital of the Joint Logistics Support Force of the Liberation Army, Jiangsu Province, Wuxi 214000, China
Abstract:Objective To explore the efficacy of Cetuximab in the treatment of elderly k-RAS wild-type metastatic colorectal cancer (mCRC), and to provide a method for the treatment of this disease. Methods A total of 68 elderly patients with k-RAS wild-type mCRC admitted to NO. 904 Hospital of the Joint Logistics Support Force of the Liberation Army from October 2015 to October 2019 were selected as the research subjects. According to random number table method, they were divided into study group and control group, with 34 cases in each group. The control group received conventional chemotherapy, and the research group received Cetuximab in addition to the control group. The therapeutic effect was evaluated after 12 weeks of continuous treatment. The recent anti-tumor effect and the changes of tumor markers before and after treatment were compared between the two groups, and the safety of the two groups was statistically analyzed. Results The clinical control rate in the study group was higher than that in the control group, and the difference was statistically significant (P < 0.05). Before treatment, there were no significant differences in serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 199 between the two groups (P > 0.05). After treatment, CEA and CA199 in both groups were lower than those before treatment, and those in the study group were lower than those in the control group, with statistical significance (all P < 0.05). There was no statistical significance in the incidence of acne-like rash, myelosuppression, liver function injury and digestive tract reaction between the two groups (P > 0.05). Conclusion Cetuximab treatment for elderly patients with k-RAS wild-type mCRC can significantly enhance the anti-tumor efficacy, reduce the level of tumor markers and the patient are well tolerated.